Select Publications
Conference Abstracts
, 2012, 'Primary HIV-1 infection (PHI) is associated with reduced CD4 cell counts in terminal ileum biopsies, but not other gut biopsy sites', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, Vol. 27, pp. 19 - 19, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000308642600039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2005, 'Regulatory T cells and the maintenance of tolerance', in TISSUE ANTIGENS, BLACKWELL PUBLISHING, AUSTRALIA, Melbourne, Vol. 66, pp. 412 - 412, presented at 35th Annual SCientific Meeting of the Australasian-Society-for-Immunology/14th International HLA and Immunogenetics Workshops, AUSTRALIA, Melbourne, 29 November 2005 - 02 December 2005, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000233542700194&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Reports
, 2021, Agenda 2025 Ending HIV Transmission in Australia: Technical paper on science, trends and targets June 2021, Sydney, http://dx.doi.org/10.26190/unsworks/28071, https://www.afao.org.au/wp-content/uploads/2021/06/Agenda-25-Technical-Paper.pdf
, 2013, Reply to "issues on results of the external quality assessment for proviral DNA testing of HIV-1 tropism in the maraviroc switch collaborative study", http://dx.doi.org/10.1128/JCM.02207-13
, 2005, Immune Response to HIV
, 2001, Monitoring resistance to antiretroviral treatments for HIV infection, 17
Patents
, 2020, Gene therapeutic for the treatment of HIV and uses thereof, Patent No. Germany, Spain, France, United Kingdom, Italy patent no. 3294895, https://worldwide.espacenet.com/publicationDetails/biblio?II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20180321&CC=EP&NR=3294895A1&KC=A1
, 2019, Methods for discriminating between HIV-1 and lentiviral vectors, Patent No. US patent no.10240214; Switzerland, Germany, Denmark, Spain, France, United Kingdom, Ireland, Italy, Netherlands, Sweden patent no. 3283658; US 2021 pat no. 11008630, http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=10240214.PN.&OS=PN/10240214&RS=PN/10240214
Preprints
, 2024, Self-reactive B cells traverse a perfect storm of somatic mutagenesis to cause a virus-induced autoimmune disease, http://dx.doi.org/10.1101/2024.01.07.574561
, 2023, Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia, http://dx.doi.org/10.1101/2023.08.17.23293358
, 2023, Improvement of immune dysregulation and health-related quality of life in individuals with long COVID at 24-months following SARS-CoV-2 infection, http://dx.doi.org/10.1101/2023.08.27.23294704
, 2023, Long-term serial passaging of SARS-CoV-2 reveals signatures of convergent evolution, http://dx.doi.org/10.1101/2023.11.02.565396
, 2023, TMPRSS2 activation of Omicron lineage Spike glycoprotein is regulated by Collectrin-like domain of ACE2, http://dx.doi.org/10.1101/2023.09.22.558930
, 2022, Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients, http://dx.doi.org/10.1101/2022.10.19.512954
, 2022, Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sublineages in the face of maturing antibody breadth at the population level, http://dx.doi.org/10.1101/2022.12.06.22283000
, 2022, High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells, http://dx.doi.org/10.1101/2022.07.22.22277947
, 2022, Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation: a longitudinal observational study, http://dx.doi.org/10.1101/2022.06.07.22276020
, 2022, Rapid isolation and resolution immune evasion and viral fitness across contemporary SARS-CoV-2 variants, http://dx.doi.org/10.21203/rs.3.rs-1210846/v1
, 2022, SARS-CoV-2 Omicron BA.5: Evolving Tropism and Evasion of Potent Humoral Responses and Resistance to Clinical Immunotherapeutics Relative to Viral Variants of Concern, http://dx.doi.org/10.2139/ssrn.4157473
, 2022, SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern, http://dx.doi.org/10.1101/2022.07.07.22277128
, 2022, SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern, http://dx.doi.org/10.21203/rs.3.rs-1207364/v1
, 2021, Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection, http://dx.doi.org/10.1101/2021.06.01.21257759
, 2021, Limited recovery from post-acute sequelae of SARS-CoV-2 (PASC) at eight months in a prospective cohort, http://dx.doi.org/10.1101/2021.03.29.21254211
, 2020, SARS-CoV-2 neutralizing antibodies; longevity, breadth, and evasion by emerging viral variants, http://dx.doi.org/10.1101/2020.12.19.20248567
, 2020, A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilizing immunity against SARS-CoV-2 infection in mice, http://dx.doi.org/10.1101/2020.12.10.419044
, 2020, Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies, http://dx.doi.org/10.1101/2020.12.14.422791
, 2020, SARS Coronavirus-2 microneutralisation and commercial serological assays correlated closely for some but not all enzyme immunoassays, http://dx.doi.org/10.1101/2020.12.07.20245696